Neal S McCall1, Brittany A Simone1, Minesh Mehta2, Tingting Zhan3, Kevin Ko1, Kamila Nowak-Choi4, Annaisabel Rese5, Chantel Venkataraman1, David W Andrews1, Pramila R Anne'1, Adam P Dicker1, Wenyin Shi1, Nicole L Simone6. 1. Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Sidney Kimmel Cancer Center, Bodine Center, Suite G-301, 111 South 11th Street, Philadelphia, PA, 19107, USA. 2. Department of Radiation Oncology, Miami Cancer Institute at Baptist Health South Florida, Miami, FL, USA. 3. Division of Biostatistics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA. 4. MedStar Franklin Square Medical Center, Rosedale, MD, USA. 5. University of Naples Federico II, Naples, Italy. 6. Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Sidney Kimmel Cancer Center, Bodine Center, Suite G-301, 111 South 11th Street, Philadelphia, PA, 19107, USA. Nicole.Simone@jefferson.edu.
Abstract
PURPOSE: Metabolic dysregulation has been implicated as a molecular driver of breast cancer in preclinical studies, especially with respect to metastases. We hypothesized that abnormalities in patient metabolism, such as obesity and diabetes, may drive outcomes in breast cancer patients with brain metastases. METHODS: We retrospectively identified 84 consecutive patients with brain metastases from breast cancer treated with intracranial radiation therapy. Radiation was delivered as whole-brain radiation to a median dose of 3000 cGy or stereotactic radiosurgery to a median dose of 2100 cGy. Kaplan Meier curves were generated for overall survival (OS) data and Mantel-Cox regression was performed to detect differences in groups. RESULTS: At analysis, 81 survival events had occurred and the median OS for the entire cohort was 21.7 months. Despite similar modified graded prognostic assessments, resection rates, and receptor status, BMI ≥ 25 kg/m2 (n = 45) was associated with decreased median OS (13.7 vs. 30.6 months; p < 0.001) and median intracranial progression-free survival (PFS) (7.4 vs. 10.9 months; p = 0.04) compared to patients with BMI < 25 kg/m2 (n = 39). Similar trends were observed among all three types of breast cancer. Patients with diabetes (n = 17) had decreased median OS (11.8 vs. 26.2 months; p < 0.001) and median intracranial PFS (4.5 vs. 10.3 months; p = 0.001) compared to non-diabetics (n = 67). On multivariate analysis, both BMI ≥ 25 kg/m2 [HR 2.35 (1.39-3.98); p = 0.002] and diabetes [HR 2.77 (1.454-5.274); p = 0.002] were associated with increased mortality. CONCLUSIONS: Elevated BMI or diabetes may negatively impact both overall survival and local control in patients with brain metastases from breast cancer, highlighting the importance of the translational development of therapeutic metabolic interventions. Given its prognostic significance, BMI should be used as a stratification in future clinical trial design in this patient population.
PURPOSE: Metabolic dysregulation has been implicated as a molecular driver of breast cancer in preclinical studies, especially with respect to metastases. We hypothesized that abnormalities in patient metabolism, such as obesity and diabetes, may drive outcomes in breast cancerpatients with brain metastases. METHODS: We retrospectively identified 84 consecutive patients with brain metastases from breast cancer treated with intracranial radiation therapy. Radiation was delivered as whole-brain radiation to a median dose of 3000 cGy or stereotactic radiosurgery to a median dose of 2100 cGy. Kaplan Meier curves were generated for overall survival (OS) data and Mantel-Cox regression was performed to detect differences in groups. RESULTS: At analysis, 81 survival events had occurred and the median OS for the entire cohort was 21.7 months. Despite similar modified graded prognostic assessments, resection rates, and receptor status, BMI ≥ 25 kg/m2 (n = 45) was associated with decreased median OS (13.7 vs. 30.6 months; p < 0.001) and median intracranial progression-free survival (PFS) (7.4 vs. 10.9 months; p = 0.04) compared to patients with BMI < 25 kg/m2 (n = 39). Similar trends were observed among all three types of breast cancer. Patients with diabetes (n = 17) had decreased median OS (11.8 vs. 26.2 months; p < 0.001) and median intracranial PFS (4.5 vs. 10.3 months; p = 0.001) compared to non-diabetics (n = 67). On multivariate analysis, both BMI ≥ 25 kg/m2 [HR 2.35 (1.39-3.98); p = 0.002] and diabetes [HR 2.77 (1.454-5.274); p = 0.002] were associated with increased mortality. CONCLUSIONS: Elevated BMI or diabetes may negatively impact both overall survival and local control in patients with brain metastases from breast cancer, highlighting the importance of the translational development of therapeutic metabolic interventions. Given its prognostic significance, BMI should be used as a stratification in future clinical trial design in this patient population.
Entities:
Keywords:
Brain metastases; Breast cancer; Diabetes; Obesity; Radiation; Radiosurgery
Authors: Heather M McGee; Dadi Jiang; David R Soto-Pantoja; Avinoam Nevler; Amato J Giaccia; Wendy A Woodward Journal: Clin Cancer Res Date: 2019-02-05 Impact factor: 12.531
Authors: Jennifer A Ligibel; Luke Huebner; Hope S Rugo; Harold J Burstein; Debra L Toppmeyer; Carey K Anders; Cynthia Ma; William T Barry; Vera Suman; Lisa A Carey; Ann H Partridge; Clifford A Hudis; Eric P Winer Journal: JNCI Cancer Spectr Date: 2021-04-12
Authors: Rachel A Sabol; Vidal A Villela; Alexandra Denys; Benjamin T Freeman; Alifiani B Hartono; Rachel M Wise; Mark A A Harrison; Maxwell B Sandler; Fokhrul Hossain; Lucio Miele; Bruce A Bunnell Journal: Int J Mol Sci Date: 2020-04-15 Impact factor: 5.923
Authors: Anuradha A Shastri; Joseph Lombardo; Samantha C Okere; Stephanie Higgins; Brittany C Smith; Tiziana DeAngelis; Ajay Palagani; Kamryn Hines; Daniel A Monti; Stella Volpe; Edith P Mitchell; Nicole L Simone Journal: Int J Mol Sci Date: 2021-12-24 Impact factor: 5.923